Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) CEO Sells $156,229.38 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin Palleiko sold 10,034 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $156,229.38. Following the completion of the transaction, the chief executive officer directly owned 442,883 shares in the company, valued at $6,895,688.31. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

KalVista Pharmaceuticals Stock Performance

KALV opened at $15.76 on Friday. The company has a 50 day simple moving average of $15.50 and a two-hundred day simple moving average of $13.97. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21. The firm has a market cap of $796.67 million, a P/E ratio of -3.99 and a beta of -0.19. KalVista Pharmaceuticals, Inc. has a 1-year low of $9.23 and a 1-year high of $19.00.

Analyst Upgrades and Downgrades

KALV has been the topic of a number of recent analyst reports. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Needham & Company LLC lifted their target price on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Finally, Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a research report on Tuesday, November 11th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets grew its holdings in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 1,292 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at approximately $55,000. Wolverine Asset Management LLC purchased a new position in shares of KalVista Pharmaceuticals in the third quarter valued at $57,000. Truvestments Capital LLC increased its position in KalVista Pharmaceuticals by 253.8% in the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after purchasing an additional 3,360 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in KalVista Pharmaceuticals in the third quarter worth $63,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.